First Time Loading...
N

Noile-Immune Biotech Inc
TSE:4893

Watchlist Manager
Noile-Immune Biotech Inc
TSE:4893
Watchlist
Price: 153 JPY -0.65% Market Closed
Updated: May 13, 2024
Section:
 

Wall Street
Price Targets

Price Targets Summary
Noile-Immune Biotech Inc

Wall Street analysts forecast Noile-Immune Biotech Inc stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Noile-Immune Biotech Inc is 448.8 JPY with a low forecast of 444.4 JPY and a high forecast of 462 JPY.

Lowest Forecast
Wall Street Target
444.4 JPY
190% Upside
Average Forecast
Wall Street Target
448.8 JPY
193% Upside
Highest Forecast
Wall Street Target
462 JPY
202% Upside
Lowest
Price Target
444.4 JPY
190% Upside
Average
Price Target
448.8 JPY
193% Upside
Highest
Price Target
462 JPY
202% Upside
Noile-Immune Biotech Inc Competitors:
Price Targets
MRNA
Moderna Inc
12% Upside
I
TIL
Instil Bio Inc
144% Upside
TSVT
2Seventy Bio Inc
149% Upside
LEGN
Legend Biotech Corp
96% Upside
MRNA
Moderna Inc
12% Upside
I
TIL
Instil Bio Inc
144% Upside
TSVT
2Seventy Bio Inc
149% Upside
LEGN
Legend Biotech Corp
96% Upside
DVAX
Dynavax Technologies Corp
138% Upside
ATORX
Alligator Bioscience AB
171% Upside
C
049960
Cell Biotech Co Ltd
363% Upside
CRIS
Curis Inc
41% Upside

Revenue
Forecast

Revenue Estimate
Noile-Immune Biotech Inc

For the last 2 years the compound annual growth rate for Noile-Immune Biotech Inc's revenue is 77%. The projected CAGR for the next 3 years is 1%.

77%
Past Growth
1%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Noile-Immune Biotech Inc

Operating Income forecast
is not available for
Noile-Immune Biotech Inc

Net Income
Forecast

Net Income Estimate
Noile-Immune Biotech Inc

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Noile-Immune Biotech Inc's stock price target?
Price Target
448.8 JPY

According to Wall Street analysts, the average 1-year price target for Noile-Immune Biotech Inc is 448.8 JPY with a low forecast of 444.4 JPY and a high forecast of 462 JPY.

What is Noile-Immune Biotech Inc's Revenue forecast?
Projected CAGR
1%

For the last 2 years the compound annual growth rate for Noile-Immune Biotech Inc's revenue is 77%. The projected CAGR for the next 3 years is 1%.

ALPHA SPREAD
Join more than 136,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.